Purpose The objective of this study is to generate reliable Ki parametric images from a shortened [18F]FDG total-body PET for clinical applications using a self-supervised neural network algorithm. Methods We proposed a self-supervised neural network algorithm with Patlak graphical analysis (SN-Patlak) to generate Ki images from shortened dynamic [18F]FDG PET without 60-min full-dynamic PET-based training

Purpose Prostate-specific membrane antigen positron emission tomography (PSMA-PET) guided targeted biopsy has shown potential for detecting more prostate cancer (PCa) cases. However, relying exclusively on imaging may risk missing lesions, an issue that could be addressed by incorporating radiation-guided technology. Accordingly, we aimed to develop a novel PSMA radiotracer with a long half-life,

Purpose This study examined the impact of venlafaxine and bupropion on the detection of nigrostriatal degeneration by dopamine transporter (DAT)-SPECT. Methods 43 patients (70.7 ± 8.6y, 44% female) with [123I]FP-CIT-SPECT under venlafaxine (n = 26, 37.5-225 mg/d), bupropion (n = 16, 150 or 300 mg/d) or both (n = 1) were included retrospectively. The striatal specific [123I]FP-CIT binding ratio (SBR)

Introduction Bacterial infections pose major challenges in medicine. To guide effective infection treatment, faster and more accurate diagnostic modalities are needed. Bacteria-targeted molecular imaging can meet these needs. The present study was aimed at the in vivo evaluation of two 18F-vancomycin-based PET tracers, for detection of deep-seated Gram-positive bacterial infections. These tracers were

Purpose Noninvasive angiogenesis visualization is essential for evaluating tumor proliferation, progression, invasion, and metastasis. This study aimed to translate the heterodimeric PET tracer [68Ga]Ga-HX01, which targets integrin αvβ3 and CD13 in neovascularization, into phase I clinical study. Methods This study enrolled 12 healthy volunteers (phase Ia) and 10 patients with malignant tumors (phase

Purpose The role of fibroblast activation protein (FAP)-targeted imaging in systemic vasculitis is currently unclear. We aimed to evaluate the clinical value of fluorine-18-labeled FAP inhibitor 42 ([18F]FAPI-42) in patients with systemic vasculitis and to compare with [18F]fluorodeoxyglucose (FDG) imaging. Methods Patients with systemic vasculitis who underwent dual-tracer PET/CT([18F]FDG and [18F]FAPI)

Purpose Deep convolutional neural networks (CNN) hold promise for assisting the interpretation of dopamine transporter (DAT)-SPECT. For improved communication of uncertainty to the user it is crucial to reliably discriminate certain from inconclusive cases that might be misclassified by strict application of a predefined decision threshold on the CNN output. This study tested two methods to incorporate

Purpose Radiomics has revolutionized clinical research by enabling objective measurements of imaging-derived biomarkers. However, the true potential of radiomics necessitates a comprehensive understanding of the biological basis of extracted features to serve as a clinical decision support. In this work, we propose an end-to-end framework for the in silico simulation of [18F]FLT PET imaging process

Purpose To evaluate right ventricular (RV) uptake measured by quantitative [99mTc]Tc-DPD SPECT/CT to investigate its role in predicting and evaluating prognosis and therapeutic outcomes in patients with transthyretin amyloid cardiomyopathy (ATTR-CA). Methods Patients with ATTR-CA were consecutively enrolled for quantitative [99mTc]Tc-DPD SPECT/CT. Ventricular amyloid burden was quantified by SUVmax

Purpose Recent development in positron emission tomography (PET) dramatically increased the effective sensitivity by increasing the geometric coverage leading to total-body PET imaging. This encouraging breakthrough brings the hope of ultra-low dose PET imaging equivalent to transatlantic flight with the assistance of deep learning (DL)-based methods. However, conventional DL approaches face limitations

Purpose There is a need for biomarkers in psychiatry to improve diagnosis, prognosis and management, and with confirmed value in follow-up care. Radionuclide imaging, given its molecular imaging characteristics, is well-positioned for translation to the clinic. This systematic review lays the groundwork for integrating PET and SPECT imaging in the clinical management of schizophrenia-spectrum disorders

Objective To investigate the relationship of synaptic loss with glucose metabolism and dopaminergic transporters in Parkinson’s disease (PD) patients. Methods A total of 16 patients with PD and 11 age-matched healthy controls underwent positron emission tomography (PET) with the tracers [18F]SynVesT-1, a ligand for the presynaptic terminal marker synaptic vesicle protein 2 A (SV2A), and FDG. PD patients

Purpose Radiolabeled probes targeting prostate-specific membrane antigen (PSMA) have been used in prostate cancer. Moreover, PSMA is also overexpressed on neovessels in hepatocellular carcinoma (HCC). This study aimed to preliminarily evaluate the diagnostic effectiveness of [68Ga]Ga-PSMA-617 PET/MRI for HCC. Methods Patients suspected of HCC were prospectively enrolled in this single-center study

Purpose Dopamine transporter imaging is routinely used in Parkinson’s disease (PD) and atypical parkinsonian syndromes (APS) diagnosis. While [11C]CFT PET is prevalent in Asia with a large APS database, Europe relies on [123I]FP-CIT SPECT with limited APS data. Our aim was to develop a deep learning-based method to convert [11C]CFT PET images to [123I]FP-CIT SPECT images, facilitating multicenter studies

Purpose Dual-energy (DE) CT enables material decomposition by using two different x-ray energies and may be combined with PET for improved multimodality imaging. However, this increases radiation dose and may require a hardware upgrade due to the added second x-ray CT scan. The recently proposed PET-enabled DECT method allows dual-energy imaging using a conventional PET/CT scanner without the need

Background To develop the extracellular matrix metalloproteinase inducer (CD147)-targeting therapeutic strategies, accurate detection of CD147 expression in tumors is crucial. Owing to their relatively low molecular weights and high affinities, nanobodies (Nbs) may be powerful candidates for cancer diagnosis and therapy. In this study, we developed a novel CD147-targeted nanobody radiotracer, [124I]I-NB147

Purpose While early diagnosis is crucial, as new treatments can significantly slow the progression of the disease, there is growing evidence on the application of novel imaging techniques for detecting transthyretin amyloidosis (ATTR) in pre-symptomatic stages. This study aimed to evaluate the utility of pre-symptomatic scintigraphic imaging cascade screening for early detection of ATTR. Methods During

Background and purpose Enhanced lesion detection in prostate cancer is observed with late [68 Ga]Ga-PSMA-11 PET/CT imaging compared to standard [68 Ga]Ga-PSMA-11 PET/CT imaging (50–100 min p.i.). However, the poor image quality of late imaging using short axial field of view (SAFOV) PET/CT has hindered its sole clinical adoption. Conversely, the image quality of late imaging with a long axial field

Purpose Somatostatin receptor (SSTR) antagonists have recently emerged as preferable radiotracers for SSTR-targeted imaging and therapy. This study aimed to design a novel SSTR antagonist, [18F]AlF-NOTA-Asp2-PEG2-JR11, and compare its preclinical performance with the previously reported antagonist, [18F]AlF-NOTA-JR11, and the agonist [68Ga]Ga-DOTA-TATE. Methods [18F]AlF-NOTA-Asp2-PEG2-JR11 was synthesized

Purpose This study by the EANM radiobiology working group aims to analyze the efficacy and toxicity of targeted radionuclide therapy (TRT) using radiopharmaceuticals approved by the EMA and FDA for neuroendocrine tumors and prostate cancer. It seeks to understand the correlation between physical parameters such as absorbed dose and TRT outcomes, alongside other biological factors. Methods We reviewed

Purpose Ultrasmall silver sulfide nanoparticles (Ag2S-NP) have been identified as promising contrast agents for a number of modalities and in particular for dual-energy mammography. These Ag2S-NP have demonstrated marked advantages over clinically available agents with the ability to generate higher contrast with high biocompatibility. However, current synthesis methods for inorganic nanoparticles

Purpose 177Lu-OncoFAP-23 is a novel FAP-targeted radioligand therapeutic (RLT) with high and prolonged tumor residence time and promising preclinical efficacy. In this work, we investigated the correlation between the injected molar dose and the in vivo tumor-to-organ ratios and tumor-targeting performance of 177Lu-OncoFAP-23. Methods We evaluated the quantitative biodistribution profile of 177Lu-OncoFAP-23